Quarterly ResultMay 12, 2026, 04:15 PM
PepGen Q1 Net Loss $17.8M; PGN-EDODM1 5mg/kg Data Favorable
AI Summary
PepGen Inc. reported a net loss of $17.8 million, or $(0.26) per share, for Q1 2026, a significant reduction from $30.2 million in Q1 2025. The company also announced favorable safety and efficacy data from the 5 mg/kg cohort of its PGN-EDODM1 FREEDOM2 trial for DM1, with the 10 mg/kg cohort fully enrolled and data expected in 2H 2026. Despite a partial clinical hold by the FDA on the FREEDOM2 study, PepGen stated the timing of the ongoing trial remains unaffected and its $132.3 million cash balance provides funding into 2H 2027.
Key Highlights
- PGN-EDODM1 5 mg/kg cohort demonstrated favorable safety, splicing, and vHOT data.
- PGN-EDODM1 10 mg/kg MAD cohort fully enrolled; data expected in 2H 2026.
- FDA placed a partial clinical hold on FREEDOM2 study; timing of ongoing study not impacted.
- Cash, cash equivalents, and marketable securities totaled $132.3 million as of March 31, 2026.
- Net loss for Q1 2026 was $17.8 million, or $(0.26) per share, down from $30.2 million in Q1 2025.
- Research and Development Expenses decreased to $13.0 million in Q1 2026 from $25.4 million in Q1 2025.
- Existing cash is sufficient to fund operations into 2H 2027, through 12.5 mg/kg MAD readout.
Price Impact
More from PEPG